Gnubiotics Sciences SA announces a CHF 2.6 million Series A1 fundraise

Gnubiotics Sciences SA, a swiss biotech dedicated to revolutionizing microbiome health in humans and animals, has secured CHF 2.6 million in a series A1 which included current shareholders and new investors.
In parallel, Gnubiotics has also secured a CHF 787’000 loan from UBS backed by the Canton de Vaud and Swiss Confederation. With this new round of funding and loan, Gnubiotics’ total funds raised add up to CHF 9.5 million.

Read full press release